Efficacy And Safety Of A New Clobetasol Propionate 0.05% Foam In Alopecia Areata: A Randomized, Double-Blind Placebo-Controlled Trial

The study evaluated the efficacy, safety, and tolerability of a new clobetasol propionate 0.05% foam (CF) in treating moderate to severe alopecia areata (AA) in a 24-week, randomized, double-blind, placebo-controlled trial involving 34 patients. Results showed that 89% of CF-treated sites experienced greater hair regrowth compared to 11% of placebo-treated sites, with significant improvements in hair regrowth scores (RGS) and alopecia grading scores (AGS). By the end of the trial, 47% of CF-treated patients had a RGS of 2 (hair regrowth of more than 25%), and 25% had a RGS of 3 (hair regrowth of 50%). The treatment was well-tolerated with minimal side effects, such as folliculitis in two patients, and no significant changes in cortisol and ACTH levels. The new CF formulation was concluded to be an effective, safe, and well-tolerated treatment for AA with good patient compliance.